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doi:10.1016/j.bpobgyn.2012.01.002Malignant ovarian germ-cell tumours account for about 5% of all
ovarian malignancies and typically present in the teenage years.
They are almost always unilateral and are exquisitely chemo-
sensitive. As such, the surgical approach in young women with
such tumours conﬁned to a single ovary should aim to preserve
fertility. In early disease, a unilateral salpingo-oophorectomy with
careful surgical staging is of great importance in selecting appro-
priate adjuvant therapy. In advanced disease, the role of aggressive
cytoreducation is not well deﬁned, and removal of both ovaries
does not confer improvement in outcome. Bleomycin, etoposide
and cisplatin combination chemotherapy is regarded as the gold
standard for adjuvant therapy. Studies evaluating ovarian and
reproductive capacity after conservative surgery and chemo-
therapy for malignant ovarian germ-cell tumours have consistently
demonstrated excellent prognosis, with the return of normal
menstrual function and fertility rates in these women with no
increase in the risk of teratogenicity.
 2012 Elsevier Ltd. All rights reserved.Introduction
Malignant ovariangerm-cell tumours (MOGCTs) account for 5%of all ovarianmalignancies inWestern
countries. Because they principally occur during adolescence and early adulthood, decisions onx: þ65 6779 4753.
Low).
d. All rights reserved.
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women with advanced non-dysgerminomatous disease died. Even for the exquisitely radiosensitive
dysgerminomas, women who had been radiated were left with their fertility destroyed. Subsequent
introduction of effective combination chemotherapy brought about dramatic improvements in the
prognosis for MOGCTs. These have largely been extrapolated from the experience of treating the more
common testicular germ-cell tumours. Many randomised-controlled trials for testicular germ-cell
tumours have provided a strong evidence base for treatment decision making in MOGCT.1,2 In the
evolution of care, combination chemotherapy using vincristine, dactinomycin, and cyclophosphamide
(VAC regimen) was able to achieve cure rates of 86% in women with International Federation of Gyne-
cology and Obstetrics (FIGO) Stage I non-dysgerminomatous disease,3 but women with metastatic
disease then had a 50–70%mortality.3,4 The introduction of cisplatin-containing drug regimens, notably
the BEP (bleomycin, etoposide and cisplatin) regimen from the 1980s onward, resulted in a 5-year
survival rate of up to 100% for dysgerminomas and 85% for non-dysgerminomatous MOGCT.5–7
Prompt initiation of appropriate chemotherapy is the critical factor for young women with an
advanced MOGCT.8 Contemporary principles of surgery for MOGCTs dictate that fertility preservation is
appropriate even in the face of extensive metastatic disease if fertility is desired, because there is no
evidence that removing an uninvolved ovary enhances survival. Hence, the focus of subsequent studies
on MOGCT has shifted to long-term sequelae for these young women, with particular emphasis on
ovarian and reproductive function, including teratogenicity, especially after combination chemotherapy.Classiﬁcation of malignant ovarian germ-cell tumours
The current 2003 World Health Organization classiﬁcation of system for MOGCT is as shown in
Table 1.9Table 1
Histological classiﬁcation of malignant ovarian germ-cell tumours.9
Primitive germ-cell tumours
Dysgerminoma
Yolk-sac tumour
Polyvesicular vitelline tumour
Glandular variant
Hepatoid variant
Embryonal carcinoma
Polyembryoma
Non-gestational choriocarcinoma
Mixed germ-cell tumour, specify components
Biphasic or triphasic teratoma
Immature teratoma
Mature teratoma
Solid
Cystic, dermoid cyst
Fetiform teratoma, homunculus
Monodermal teratoma and somatic-type tumours associated with biphasic or triphasic teratoma
Thyroid tumour group
Carcinoid group
Neuroectodermal tumour group
Carcinoma group
Melanocytic group
Sarcoma group
Sebaceous tumour group
Pituitary-type tumour group
Retinal anlage tumour group
Others
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nomatous tumour, which is the most common type and the counterpart of the male seminoma,
and non-dysgerminomatous tumours. The most common types of non-dysgerminomatous
tumours are yolk-sac tumour, immature teratoma, and mixed germ-cell tumours. The embry-
onal carcinomas, non-gestational choriocarcinomas, and polyembryomas are much less common
varieties.
Epidemiology and clinical presentation
Although 20–25% of all benign and malignant ovarian neoplasms are of germ-cell origin, only
about 3% of these tumours are malignant.10 Although MOGCTs account for fewer than 5% of all
ovarian cancers in Western countries, they represent as much as 15% of ovarian cancers in Asian and
black societies, where epithelial ovarian cancers are much less common. In the ﬁrst 2 decades of life,
almost 70% of ovarian tumours are of germ-cell origin, and one-third of these are malignant.10,11
Malignant ovarian germ-cell tumours also are seen in the third decade, but thereafter they
become quite rare.
These tumours typically present in the teenage years, with symptoms of abdominal pain and
a palpable pelvi-abdominal mass. In about 10% of women, the mass may grow rapidly, resulting in
acute abdominal pain related to capsular distention, necrosis, haemorrhage, rupture or torsion of the
ovarian tumour. The initial workup should include serum tumour markers, pelvic sonography and
a computed tomography of the abdomen and pelvis if extra-ovarian metastases are suspected. A
radiograph of the chest is important because MOGCTs can metastasise to the lungs or mediastinum.
The tumour markers should include serum alpha-fetoprotein (AFP), lactate dehydrogenase (LDH), beta
human chorionic gonadotropin (b-hCG) and cancer antigen 125 titers. Yolk-sac tumour and ovarian
choriocarcinoma produce AFP and b-hCG, respectively. Both embryonal carcinoma and polyembryoma
may produce b-hCG and AFP, the former more commonly. A small percentage of dysgerminomas may
display elevated levels of LDH or may produce low levels of b-hCG related to the presence of multi-
nucleated syncytiotrophoblastic giant cells. About one-third of immature teratomas produce AFP.
Mixed germ-cell tumoursmay produce any of the tumourmarkers, or none, depending on the type and
quantity of elements present.12–14 Elevated serum tumour markers can serve as an adjunct in initial
diagnosis, monitoring during therapy, and post-treatment surveillance. A karyotype should ideally be
obtained preoperatively on all premenarchal girls because of the propensity of these tumours to arise
in dysgenetic gonads.13,14
Surgical treatment
The modern surgical approach to MOGCTs has been derived from data that emerged from several
large studies from the Armed Forces Institute of Pathology in the 1970s15–17 and from other relatively
large studies.18–21 These articles underscored the ﬁnding that most MOGCTs are unilateral, with the
exception of pure dysgerminomas, which are bilateral in 10–15% of cases, although bilaterality in up to
23.1% has been reported from a study of 26 cases at Yale University.22 Bilateral involvement may also
occur in cases of advanced disease in which there is metastasis from one ovary to the other.23 These
large studies also showed that benign cystic teratomas are found on the contralateral ovary in 5–10% of
women with MOGCTs. Therefore, if a benign dermoid cyst is discovered, only ovarian cystectomy with
preservation of normal ovarian tissue is recommended.22,24,25
A unilateral salpingo-oophorectomy, with preservation of the contralateral ovary and the uterus, is
considered the appropriate surgical treatment for women with MOGCT.12,23–30 In women with
advanced disease (e.g. para-aortic lymph-node metastases), preservation of reproductive function is
also possible, particularly if the contralateral ovary is normal.22,25–27 Evidence from several large
studies3,4,15–17,20,21,31 suggests at least equivalent survival after conservative surgery (i.e. unilateral
salpingo-oophorectomy) compared with bilateral salpingo-oophorectomy with or without hysterec-
tomy. Review of the data from the Gynecologic Oncology Group4 showed that 44 out of 70 primary
lesions treated with VAC were Stage I and none was Stage IB. Removing both ovaries did not seem to
improve survival.
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carrying out conservative surgery to preserve ovarian function and fertility for most young women
with MOGCTs32 (Table 2).
During surgery, routine biopsy of the contralateral ovary should be avoided. Although occult
bilaterality has been reported, biopsy of the contralateral ovary could lead to future infertility related to
peritoneal adhesions or ovarian failure.23,38 Meticulous technique and the avoidance of unnecessary
surgery are therefore of paramount importance. Buttram and Vaquero39 reported on 59 women with
previous ovarianwedge resection, and 40 of whomwere subsequently found to have pelvic adhesions.
Conversely, Weinstein and Polishuk38 reviewed 198 women with tubal factor infertility, and found 28
with a history of ovarian-wedge resection. Bilateral involvement in the absence of metastatic disease
(i.e. Stage IB disease) is a rare occurrence in MOGCT. In a study from Queensland,26 contralateral
ovarian biopsy was carried out in sevenwomen, and none showed occult involvement. A recurrence in
the contralateral ovary still could be treated by local resection or cystectomy followed by chemo-
therapy if fertility was desired, thereby preserving some normal ovarian tissue. Therefore, to carry out
routine contralateral ovarian-wedge resections for all women with early stage MOGCT would be
unproductive. A long-term study of ovarian function after conservative surgery for benign pelvic
conditions40 concluded that therewere no signiﬁcant effects on ovulatory andmenstrual function over
a prolonged follow-up period. In the event of bilateral macroscopic involvement, unilateral or bilateral
ovarian cystectomy is an attractive option,41 especially when combined with postoperative chemo-
therapy, as long as the woman does not have dysgenetic gonads. This surgical option has not beenwell
studied.
Chemotherapy
Many of the recent advances in combination chemotherapy for MOGCTs have arisen from studies of
testicular carcinoma, the male counterpart, which is 10 times more common. The ﬁrst effective
combination chemotherapy regimen for advanced MOGCT was the VAC regimen. Despite a high
response rate, over 50% of women with advanced MOGCTs died of the disease.3,33 The introduction of
cisplatin-based chemotherapy led to a signiﬁcant improvement in survival for women with testicular
tumours42,43 The PVB regimen (cisplatin, vinblastine, and bleomycin) proved to be active and more
effective than the VAC regimen in women with MOGCTs.44–48 Subsequently, the substitution of eto-
poside for vinblastine proved to be equally active but less toxic in the treatment of women with
testicular carcinoma.43 This was incorporated into the treatment of MOGCTs, with bleomycin, etopo-
side, and cisplatin (BEP regimen) becoming the most widely used chemotherapeutic regimen.44,49 The
overall survival of women treated with platinum-based chemotherapy currently ranges from 87%5,50 to
98%.44,49
The treatment policy at our centre has been surgery alone for surgically staged and histologically
conﬁrmed Stage IA pure dysgerminomas and low-grade immature teratomas.51 All other women
receive adjuvant BEP chemotherapy. On the basis of promising data, however, from Bonazzi et al.,52Table 2
Type of surgery and survival.
Study Survival (number of women)
Ovarian conservation % Bilateral oophorectomy %
Slayton et al.33 22/28 79 7/11 64
Krepart et al.34 5/5 100 d
Schwartz35 17/17 100 2/2 100
Gershenson et al.20 12/15 80 3/6 50
Creasman et al.36 19/19 100 11/13 85
Low et al.25 55/56 98 7/8 88
Khi et al.27 43/43 100 6/6 100
Chan et al.32 97.9 95.6
Zanetta et al.37 135/138 98 27/31 87
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and Baranzelli et al.,57 a strategy of surgery plus close clinical, radiological and serological surveillance
only, for surgical stage I MOGCT, is emerging as a safe option. Surgical staging includes assessment of
peritoneal ﬂuid cytology, biopsy of any suspicious areas on the peritoneal surfaces, retroperitoneal
lymph-node sampling, including the pelvic and high para-aortic lymph nodes, and an infracolic
omentectomy. Women referred with an incompletely staged dysgerminoma or low-grade immature
teratoma apparently conﬁned to the ovary have their histology reviewed, are evaluated with tumour
markers (lactate dehydrogenase, AFP and b-hCG) to detect non-dysgerminomatous elements, and
undergo a computed tomography scan to detect any unsuspected residual tumour. If these studies are
normal, the woman is not surgically restaged and is followed with tumour markers and computed
tomography scans or ultrasonography. Using this approach, a case study from Australia reported
a 98.2% recurrence-free survival rate for women with Stage I disease and 88.9% for women with
advanced-stage disease in the chemotherapy group.25 Thomas et al.58 reported a 10-year survival rate
of 88.6% after conservative surgery for women with dysgerminoma conﬁned to the ovary; less than
10 cm in size; with an intact, smooth capsule unattached to other organs; and without ascites.58
Women with recurrent dysgerminoma can also be successfully salvaged with systemic chemo-
therapy (BEP regimen).44
Ovarian function
The long-term effect of antineoplastic chemotherapy on ovarian function has been studied
extensively, especially in women treated for various malignancies, such as Hodgkin’s disease,
leukaemia, trophoblastic disease and breast carcinoma.59–64 The observed histologic changes in the
ovaries of women receiving chemotherapy include cortical ﬁbrosis, reduction in number of follicles,
and impaired follicular maturation.65–67 These changes lead to increased serum gonadotropins and
a decrease in serum oestradiol. Alkylating agents in particular can cause amenorrhoea, although
secondary sexual characteristics related to hormonal function generally are less disturbed.68
Busulfan,69 chlorambucil,70 and cyclophosphamide61,71–73 have been associated with irregular
menses and amenorrhea in adult women. Short-term intensive chemotherapy, however, particularly
using antimetabolites such as methotrexate,63,74 vinca alkaloids such as vincristine,74 and anthracy-
cline antibiotics such as dactinomycin,63 seems to affect ovarian function less commonly. Factors such
as cumulative drug dose, duration of therapy, and age at treatment have been reported to inﬂuence
the incidence of ovarian dysfunction63,72,74,75 in adult women. Low et al.25 reported that 62% of
women undergoing chemotherapy were amenorrheic during treatment, but 92% resumed regular
menses on completing chemotherapy.25 In a study from MD Anderson Cancer Center,76 68% of
women maintained regular menses after completing chemotherapy for MOGCT, and 83% had regular
periods at the time of follow up. In the study by Wu et al.77 from Beijing, 19 out of 20 postpubertal
women resumed regular menses after completing chemotherapy for MOGCT. In another report by
Pektasides et al.,78 16 out of 17 women undergoing cisplatin, vincristine, methotrexate, bleomycin,
actinomycin D, cyclophosphamide, etoposide (POMB/ACE) chemotherapy for MOGCT resumed
menses at a median time of 4.5 months after chemotherapy, indicating no permanent impairment of
gonadal function even with POMB/ACE chemotherapy. Several studies61,62,75,79–81 have shown that
the prepubertal ovary is more resistant to the adverse effects of chemotherapy. It remains unclear
whether the use of oral contraceptives during chemotherapy has a protective effect on ovarian
function. Chapman and Sutcliffe82 reported that ﬁve out of six patients treated with combination
chemotherapy and the oral contraceptive pill for Hodgkin’s disease had normal menses and normal
serum gonadotrophins at the completion of study, whereas Whitehead et al.64 found that seven out of
nine women who received the oral contraceptive pill and combination chemotherapy for Hodgkin’s
disease had oligoamenorrhea. In a recent paper by Weinberg et al.,83 14 women with MOGCT
underwent fertility-sparing surgery followed by adjuvant chemotherapy. All were on oral contra-
ceptive pills during chemotherapy. The investigators found a 100% return to normal menstrual
function within 1 year after completing chemotherapy, and one case of menarche occurring 8 months
after completing chemotherapy. The results suggest that hormonal suppression with oral contra-
ceptives may have been protective of ovarian function.
Table 3
Reproductive function after fertility-preserving surgery and chemotherapy for malignant ovarian germ-cell tumours.
Study Number of women attempting pregnancy Number of live births Infertility
Khi et al.27 6 8 1: male factor
Low et al.25 20 14 1: not investigated
Gershenson et al.87 34 37 10: unspeciﬁed
Weinberg et al.83 10 14 2: successful in-vitro fertilisation
Zanetta et al.37 20 26 4: unspeciﬁed
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Successful pregnancies after treatment with combination chemotherapy have been documented for
Hodgkin’s disease,59,60,64,84 non-Hodgkin’s lymphoma,85 and leukaemia.85 Many studies now consis-
tently show that reproductive capacity basically is unaffected after chemotherapy8,22,25–27,35,47,86 for
MOGCTand that healthy pregnancies can be anticipated. The true reproductive potential in any of these
cohorts is, of course, difﬁcult to ascertain because of the small numbers and relatively short duration of
follow up in these youngwomen,many of whom are not desirous of childbearing, even after treatment.
The rate of infertility reported among women attempting conception after treatment for MOGCT
ranges from 5%25 to about 10%.76 This corresponds to the background incidence rate of infertility in the
normal population (Table 3).
Teratogenicity
The risk of congenital malformations in the offspring of women treatedwith chemotherapy also has
been a concern. The risk is highest if chemotherapy is administered during the ﬁrst trimester of
pregnancy, especially when antimetabolites (e.g. methotrexate) and alkylating agents are used.
Chemotherapy administration during the second and third trimesters generally is not associated
with an increase in fetal anomalies, although to our knowledge the number of women studied to date is
relatively small.68 McKeen et al.88 reported a high incidence rate of congenital abnormalities in the
infants of women treated with combination chemotherapy for Hodgkin’s lymphoma, but a subsequent
study by the same investigators involving 133 pregnancies in 66 women with malignant neoplasms89
suggested that the unfavourable pregnancy outcomes were not linked to genetic damage to oocytes.
Other studies evaluating pregnancies in women previously treated with modern chemotherapy for
MOGCTs do not demonstrate any signiﬁcant increased risk of teratogenicity.25,27,60,64,67,85 In reports in
which VAC,76 PVB,77 and POMB/ACE combination78 chemotherapy regimens were used in MOGCT,
none showed an increase in the risk of congenital abnormalities. Javaheri et al.90 reported a normal live
birth for a woman after 17 cycles of VAC regimen. In a review of 169 women by Zanetta et al.37
a miscarriage rate of 11% was recorded, which did not differ from the general population. No statis-
tical difference was found in the rates of congenital malformation between women who received
chemotherapy and those who did not.
Conclusion
Conservative, fertility-sparing surgery is the procedure of choice in young women with MOGCT
conﬁned to a single ovary. Advanced stages are not always accompanied by extensive pelvic disease
and should not be a contraindication to preservation of the uterus and contralateral ovary. With the
appropriate addition of postoperative adjuvant platinum-based combination chemotherapy, these
young women have an excellent prognosis and can expect to maintain normal ovarian function and
reproductive capacity.
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Practice points
 Malignant ovarian germ-cell tumours typically occur in the ﬁrst 2 decades of life.
 Initial clinical work up should include sonography, computed tomography scans, or both, as
well as tumour markers, including AFP, LDH, b-hCG, and Ca-125.
 Fertility-sparing surgery with unilateral salpingo-oophorectomy is the standard surgical
approach for MOGCT, along with surgical staging in apparently early disease.
 The role of aggressive surgical debulking is not well deﬁned in chemo-sensitive tumours.
 BEP chemotherapy is the regimen of choice in advanced MOGCT, whereas there is now
a trend towards close surveillance in surgical Stage 1 MOGCTs.
 After fertility-sparing surgery and BEP chemotherapy, most women will resume their
previous baseline menstrual function.
 Fertility rates approximate those of the normal population, with no signiﬁcant increase in the
risk of early pregnancy loss or teratogenicity.
Research agenda
 Safety of close surveillance for surgical stage 1 non-dysgerminomatous MOGCTs.
 Role of combined oral contraceptive pills to preserve ovarian function during chemotherapy.
 Long-term psychological, physical and sexual function after chemotherapy for MOGCT.
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